NBTXR3 + Nivolumab + Pembrolizumab
Phase 1ActiveDevelopment Stage
Radiotherapy
Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor of Liver, Squamous Cell Carcinoma of Head and Neck, Metastasis From Malignant Tumor of Cervix, Metastatic Renal Cell Carcinoma, Metastasis From Malignant Melanoma of Skin (Disorder), Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC, Metastasis From Malignant Tumor of Bladder (Disorder)
Jan 16, 2019 → Aug 30, 2027
About NBTXR3 + Nivolumab + Pembrolizumab
NBTXR3 + Nivolumab + Pembrolizumab is a phase 1 stage product being developed by Nanobiotix for Radiotherapy. The current trial status is active. This product is registered under clinical trial identifier NCT03589339. Target conditions include Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03589339 | Phase 1 | Active |
Competing Products
1 competing product in Radiotherapy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Clonidine HCl Mucoadhesive Buccal Tablet + Placebo Mucoadhesive Buccal Tablet | Monopar Therapeutics | Phase 2/3 | 57 |